Healthcare Industry News: peripheral artery disease
News Release - September 23, 2010
First European Patients Treated for Peripheral Artery Disease Using Longest Length GORE(R) VIABAHN(R) EndoprosthesisInterventionalists Find Flexible Stent – Graft Capable of Re-lining Tortuous Arteries
REGENSBURG, Germany & BAD KROZINGEN, Germany--(Healthcare Sales & Marketing Network)--W. L. Gore & Associates (Gore) announced the treatment of the first European patients with the new 25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface, the longest length stent-graft available in Europe. Piotr Kasprzak, from the Department of Vascular Surgery at the Klinikum der Universität in Regensburg, Germany, and Thomas Zeller, MD, from the Department of Angiology at the Herz-Zentrum in Bad Krozingen, Germany successfully treated patients using the Gore device.
The new 25 cm GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface is designed to cover more of the lesion in the Superficial Femoral Artery (SFA) potentially reducing the need for multiple devices. Both Dr. Kasprzak and Professor Zeller found the device to be flexible and capable of re-lining tortuous arteries.
“The procedure using the GORE VIABAHN Endoprosthesis was very smooth, and the aneurysm was completely excluded,” said Dr. Kasprzak. “Having one long device made the procedure much simpler, and ensured it went efficiently.”
“Having a long device is a huge benefit in treating the superficial femoral artery. The 25 cm stent-graft allows the interventionist to efficiently perform an endoluminal bypass of the diseased segment,” said Professor Zeller. “The nature of many lesions requires precise placement near the origin of the SFA, and with the GORE VIABAHN Endoprosthesis, I was able to accurately deploy the device.”
The manufacturing of the Gore device features a precision laser trimming technology used to remove excess material, resulting in a contoured proximal edge that may improve flow dynamics at the proximal edge. Removal of excess material at the proximal edge improves device apposition to the vessel wall when oversizing prevents device expansion to its nominal diameter. The device also incorporates the PROPATEN Bioactive Surface which utilizes end-point immobilization of derivatized heparin to the endoprosthesis luminal surface. This proprietary surface technology preserves the heparin bioactive sites such that they remain free to interact with the blood at the device surface without being consumed.
The GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface is available with a low-profile delivery system that gives interventionalists a more streamlined approach to re-line the peripheral arteries. The GORE VIABAHN Endoprosthesis is constructed with a durable, reinforced, biocompatible, ePTFE liner attached to an external nitinol stent structure. The excellent flexibility of the GORE VIABAHN Endoprosthesis enables it to better traverse tortuous areas of the SFA and conform more closely to the complex anatomy of the artery.
ABOUT W. L. GORE & ASSOCIATES
The Gore Medical Products Division has provided creative therapeutic solutions to complex medical problems for three decades. During that time, more than 30 million innovative Gore Medical Devices have been implanted, saving and improving the quality of lives worldwide. The extensive Gore Medical family of products includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia repair, soft tissue reconstruction, staple line reinforcement and sutures for use in vascular, cardiac and general surgery. Gore was recently named one of the best companies to work for by Fortune magazine for the 13th consecutive year. For more information, visit www.goremedical.com.
Products listed may not be available in all markets. GORE®, PROPATEN, VIABAHN®, and designs are trademarks of W. L. Gore & Associates.
Source: W. L. Gore
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.